Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in Unresectable Sarcoma
NCT04126993Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in sarcoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT04126993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126993.